Expression of recombinant mature lysostaphin
US6897041B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 19, 1999 |
| Grant date | May 24, 2005 |
| Priority date | — |
| Expiry date | Oct 19, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E. coli to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent staphylococcal infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.